Oncogene. 2021 Sep;40(38):5741-5751. doi: 10.1038/s41388-021-01959-3. Epub 2021 Jul 31.

The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome.

Oncogene

Francesco Rugolo, Nicolas G Bazan, Jorgelina Calandria, Bokkyoo Jun, Giuseppe Raschellà, Gerry Melino, Massimiliano Agostini

PMID: 34333551 DOI: 10.1038/s41388-021-01959-3

Abstract

Cancer cells exhibit dysregulation of critical genes including those involved in lipid biosynthesis, with subsequent defects in metabolism. Here, we show that ELOngation of Very Long chain fatty acids protein 4 (ELOVL4), a rate-limiting enzyme in the biosynthesis of very-long polyunsaturated fatty acids (n-3, ≥28 C), is expressed and transcriptionally repressed by the oncogene MYCN in neuroblastoma cells. In keeping, ELOVL4 positively regulates neuronal differentiation and lipids droplets accumulation in neuroblastoma cells. At the molecular level we found that MYCN binds to the promoter of ELOVL4 in close proximity to the histone deacetylases HDAC1, HDAC2, and the transcription factor Sp1 that can cooperate in the repression of ELOVL4 expression. Accordingly, in vitro differentiation results in an increase of fatty acid with 34 carbons with 6 double bonds (FA34:6); and when MYCN is silenced, FA34:6 metabolite is increased compared with the scrambled. In addition, analysis of large neuroblastoma datasets revealed that ELOVL4 expression is highly expressed in localized clinical stages 1 and 2, and low in high-risk stages 3 and 4. More importantly, high expression of ELOVL4 stratifies a subsets of neuroblastoma patients with good prognosis. Indeed, ELOVL4 expression is a marker of better overall clinical survival also in MYCN not amplified patients and in those with neuroblastoma-associated mutations. In summary, our findings indicate that MYCN, by repressing the expression of ELOVL4 and lipid metabolism, contributes to the progression of neuroblastoma.

© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

References

1. Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab. 2020;31:62–76. - PubMed
2. Buck MD, O’Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell. 2016;166:63–76. - PubMed
3. Sulciner ML, Gartung A, Gilligan MM, Serhan CN, Panigrahy D. Targeting lipid mediators in cancer biology. Cancer Metastasis Rev. 2018;37:557–72. - PubMed
4. DeBose-Boyd RA, Ye J. SREBPs in lipid metabolism, insulin signaling, and beyond. Trends Biochem Sci. 2018;43:358–68. - PubMed
5. Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732–49. - PubMed
6. Snaebjornsson MT, Schulze A. Tumours use a metabolic twist to make lipids. Nature. 2019;566:333–4. - PubMed
7. Riscal R, Skuli N, Simon MC. Even cancer cells watch their cholesterol! Mol Cell. 2019;76:220–31. - PubMed
8. Dickerman BA, Garcia-Albeniz X, Logan RW, Denaxas S, Hernan MA. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25:1601–6. - PubMed
9. McGregor GH, Campbell AD, Fey SK, Tumanov S, Sumpton D, Blanco GR, et al. Targeting the metabolic response to statin-mediated oxidative stress produces a synergistic antitumor response. Cancer Res. 2020;80:175–88. - PubMed
10. Yao L, Han C, Song K, Zhang J, Lim K, Wu T. Omega-3 polyunsaturated fatty acids upregulate 15-PGDH expression in cholangiocarcinoma cells by inhibiting miR-26a/b expression. Cancer Res. 2015;75:1388–98. - PubMed
11. Bhattacharjee S, Jun B, Belayev L, Heap J, Kautzmann MA, Obenaus A, et al. Elovanoids are a novel class of homeostatic lipid mediators that protect neural cell integrity upon injury. Sci Adv. 2017;3:e1700735. - PubMed
12. Jun B, Mukherjee PK, Asatryan A, Kautzmann MA, Heap J, Gordon WC, et al. Elovanoids are novel cell-specific lipid mediators necessary for neuroprotective signaling for photoreceptor cell integrity. Sci Rep. 2017;7:5279. - PubMed
13. Agbaga MP, Brush RS, Mandal MN, Henry K, Elliott MH, Anderson RE. Role of Stargardt-3 macular dystrophy protein (ELOVL4) in the biosynthesis of very long chain fatty acids. Proc Natl Acad Sci USA. 2008;105:12843–8. - PubMed
14. Zhang K, Kniazeva M, Han M, Li W, Yu Z, Yang Z, et al. A 5-bp deletion in ELOVL4 is associated with two related forms of autosomal dominant macular dystrophy. Nat Genet. 2001;27:89–93. - PubMed
15. Bazan NG. Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection. Mol Asp Med. 2018;64:18–33. - PubMed
16. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA. 2003;100:12027–32. - PubMed
17. Nohturfft A, Zhang SC. Coordination of lipid metabolism in membrane biogenesis. Annu Rev Cell Dev Biol. 2009;25:539–66. - PubMed
18. Mizutani Y, Sun H, Ohno Y, Sassa T, Wakashima T, Obara M, et al. Cooperative synthesis of ultra long-chain fatty acid and ceramide during keratinocyte differentiation. PLoS One. 2013;8:e67317. - PubMed
19. Thiam AR, Beller M. The why, when and how of lipid droplet diversity. J Cell Sci. 2017;130:315–24. - PubMed
20. Teo W, Caprariello AV, Morgan ML, Luchicchi A, Schenk GJ, Joseph JT, et al. Nile Red fluorescence spectroscopy reports early physicochemical changes in myelin with high sensitivity. Proc Natl Acad Sci USA. 2021;118:e2016897118. - PubMed
21. Agostini M, Romeo F, Inoue S, Niklison-Chirou MV, Elia AJ, Dinsdale D, et al. Metabolic reprogramming during neuronal differentiation. Cell Death Differ. 2016;23:1502–14. - PubMed
22. Petroni A, Blasevich M, La Spada P, Papini N, Galli C. Arachidonic acid synthesis and lipid metabolism in retinoic acid-differentiated neuroblastoma cells. J Lipid Mediat Cell Signal. 1996;14:39–44. - PubMed
23. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20. - PubMed
24. Piacentini M, Annicchiarico-Petruzzelli M, Oliverio S, Piredda L, Biedler JL, Melino E. Phenotype-specific “tissue” transglutaminase regulation in human neuroblastoma cells in response to retinoic acid: correlation with cell death by apoptosis. Int J Cancer. 1992;52:271–8. - PubMed
25. Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst. 1983;71:741–7. - PubMed
26. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene. 1996;13:803–12. - PubMed
27. Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, et al. A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. Cancer Res. 2011;71:404–12. - PubMed
28. Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res. 2008;68:2375–83. - PubMed
29. Depuydt P, Koster J, Boeva V, Hocking TD, Speleman F, Schleiermacher G, et al. Meta-mining of copy number profiles of high-risk neuroblastoma tumors. Sci Data. 2018;5:180240. - PubMed
30. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nat Rev Dis Prim. 2016;2:16078. - PubMed
31. Thiele CJ. Biology of pediatric peripheral neuroectodermal tumors. Cancer Metastasis Rev. 1991;10:311–9. - PubMed
32. Pieraccioli M, Nicolai S, Pitolli C, Agostini M, Antonov A, Malewicz M, et al. ZNF281 inhibits neuronal differentiation and is a prognostic marker for neuroblastoma. Proc Natl Acad Sci USA. 2018;115:7356–61. - PubMed
33. Zirath H, Frenzel A, Oliynyk G, Segerstrom L, Westermark UK, Larsson K, et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci USA. 2013;110:10258–63. - PubMed
34. Ruiz-Perez MV, Sainero-Alcolado L, Oliynyk G, Matuschek I, Balboni N, Ubhayasekera S, et al. Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma. iScience. 2021;24:102128. - PubMed
35. Amelio I, Bertolo R, Bove P, Candi E, Chiocchi M, Cipriani C, et al. Cancer predictive studies. Biol Direct. 2020;15:18. - PubMed
36. Han Y, Ye X, Wang C, Liu Y, Zhang S, Feng W, et al. Integration of molecular features with clinical information for predicting outcomes for neuroblastoma patients. Biol Direct. 2019;14:16. - PubMed
37. Han YT, Ye XF, Cheng J, Zhang SY, Feng WX, Han Z, et al. Integrative analysis based on survival associated co-expression gene modules for predicting Neuroblastoma patients’ survival time. Biol Direct. 2019;14:4. https://doi.org/10.1186/s13062-018-0229-2 . - PubMed
38. Sumsion GR, Bradshaw MS, Beales JT, Ford E, Caryotakis GRG, Garrett DJ, et al. Diverse approaches to predicting drug-induced liver injury using gene-expression profiles. Biol Direct. 2020;15:1. https://doi.org/10.1186/s13062-019-0257-6 . - PubMed
39. Mihaylov I, Kandula M, Krachunov M, Vassilev D. A novel framework for horizontal and vertical data integration in cancer studies with application to survival time prediction models. Biol Direct. 2019;14:22. https://doi.org/10.1186/s13062-019-0249-6 . - PubMed
40. Carroll PA, Diolaiti D, McFerrin L, Gu H, Djukovic D, Du J, et al. Deregulated Myc requires MondoA/Mlx for metabolic reprogramming and tumorigenesis. Cancer Cell. 2015;27:271–85. - PubMed
41. Amelio I, Bertolo R, Bove P, Buonomo OC, Candi E, Chiocchi M, et al. Liquid biopsies and cancer omics. Cell Death Discov. 2020;6:131. - PubMed
42. Harris ZN, Dhungel E, Mosior M, Ahn TH. Massive metagenomic data analysis using abundance-based machine learning. Biol Direct. 2019;14:12. - PubMed
43. Liu L, Wang G, Wang L, Yu C, Li M, Song S, et al. Computational identification and characterization of glioma candidate biomarkers through multi-omics integrative profiling. Biol Direct. 2020;15:10. - PubMed
44. Chen JC, Tyler AD. Systematic evaluation of supervised machine learning for sample origin prediction using metagenomic sequencing data. Biol Direct. 2020;15:29. - PubMed
45. Chierici M, Francescatto M, Bussola N, Jurman G, Furlanello C. Predictability of drug-induced liver injury by machine learning. Biol Direct. 2020;15:3. - PubMed
46. Bellomaria A, Barbato G, Melino G, Paci M, Melino S. Recognition mechanism of p63 by the E3 ligase Itch Novel strategy in the study and inhibition of this interaction. Cell Cycle. 2012;11:3638–48. - PubMed
47. Ciocci M, Iorio E, Carotenuto F, Khashoggi HA, Nanni F, Melino S. H2S-releasing nanoemulsions: a new formulation to inhibit tumor cells proliferation and improve tissue repair. Oncotarget. 2016;7:84338–58. - PubMed
48. Nicolai S, Pieraccioli M, Smirnov A, Pitolli C, Anemona L, Mauriello A, et al. ZNF281/Zfp281 is a target of miR-1 and counteracts muscle differentiation. Mol Oncol. 2020;14:294–308. - PubMed
49. Lamastra FR, De Angelis R, Antonucci A, Salvatori D, Prosposito P, Casalboni M, et al. Polymer composite random lasers based on diatom frustules as scatterers. Rsc Adv. 2014;4:61809–16. - PubMed
50. Pallucca R, Visconti S, Camoni L, Cesareni G, Melino S, Panni S, et al. Specificity of epsilon and Non-epsilon Isoforms of Arabidopsis 14-3-3 Proteins Towards the H+-ATPase and Other Targets. Plos ONE. 2014;9:e90764. https://doi.org/10.1371/journal.pone.0090764 . - PubMed

Publication Types

• Journal Article
• Research Support, Non-U.S. Gov't